Drug Trial Radar · NCT06581328
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Mar 27, 2025
Primary completion
May 1, 2027
Study completion Jun 1, 2028
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Sep 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Ulcerative Colitis (UC) and Crohn's Disease (CD) are long-term conditions in the gut that can cause diarrhea, swelling (inflammation), bleeding from the anus, and belly pain. The main aim of this study is to check for how many participants with UC and CD signs and symptoms disappear after 3.5 months (14 weeks) of treatment with Vedolizumab (this is called remission). Participants will be treated with Vedolizumab for approximately 1 year (50 weeks). During the first 1.5 months (6 weeks), participants will receive Vedolizumab as an infusion in the vein (called intravenously). After this, participants will receive Vedolizumab as an injection under the skin (called subcutaneously) for the rest of the treatment. Participants for whom the treatment does not seem to work well after 3.5 months (14 weeks) will stop treatment with Vedolizumab and can change to another treatment and also there will be additional required visits at 6 months (26 weeks) and at 1 year (52 weeks). All participants will be checked again 4.5 months (18 weeks) after their last treatment with Vedolizumab. During the study, participants will visit their study clinic several times.
Conditions
- Ulcerative Colitis
- Crohn's Disease
Interventions
Vedolizumab IVDrug
Vedolizumab IV infusion
Vedolizumab SCDrug
Vedolizumab SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of CD Participants With 2-item Patient-reported Outcome Measure (PRO-2) Remission at Week 14Time frame: At Week 14
- Percentage of UC Participants With PRO-2 Remission at Week 14Time frame: At Week 14
Locations
101 sites in 1 country. Site status is shown where the registry gives one.
Gastro Health
Birmingham, Alabama · Recruiting
East View Medical Research
Mobile, Alabama · Recruiting
AZ Gastro Care
Chandler, Arizona · Recruiting
Spectrum Research Institute LLC
Gilbert, Arizona · Recruiting
GI Alliance- Sun City
Sun City, Arizona · Recruiting
UAMS Health Gastroenterology Clinic
Little Rock, Arkansas · Withdrawn
Gastroenterology and Liver Institute
Escondido, California · Recruiting
Inland Empire Gastroenterology
Murrieta, California · Withdrawn
United Clinical Research Institute
Murrieta, California · Recruiting
Digestive Health Institute
Newport Beach, California · Withdrawn
Knowledge Research Center
Orange, California · Withdrawn
Medical Associates Research Group, Inc.
San Diego, California · Withdrawn
Peak Gastroenterology Associates
Colorado Springs, Colorado · Recruiting
Rocky Mountain Endocopy Centers LLC
Littleton, Colorado · Recruiting
Access Research Institute
Brooksville, Florida · Recruiting
Gastro Florida
Clearwater, Florida · Recruiting
Doral Medical Research, LLC
Hialeah, Florida · Withdrawn
Digestive and Liver Center of Florida, P.A.
Kissimmee, Florida · Recruiting
Gastro Health Research - Miami
Miami, Florida · Recruiting
Endoscopic Research, Inc.
Orlando, Florida · Recruiting
Orlando Health-Orlando Regional Medical Center
Orlando, Florida · Recruiting
Digestive and Liver Center of Florida
Orlando, Florida · Withdrawn
Gastro Health Research - Pensacola
Pensacola, Florida · Recruiting
West Central Gastroenterology d/b/a Gastro Florida
Pinellas Park, Florida · Recruiting
Digestive Healthcare of Georgia
Atlanta, Georgia · Recruiting
AGA GA Research LLC
Atlanta, Georgia · Recruiting
Atlanta Center for Gastroenterology, P.C.
Decatur, Georgia · Withdrawn
Yapp, Rockford M.D. (Private Practice)
Downers Grove, Illinois · Recruiting
GI Alliance - Glenview
Glenview, Illinois · Recruiting
Avicenna Clinical Research - Gastroenterology and Internal Medicine Specialists
Lake Barrington, Illinois · Recruiting
Suburban Gastroenterology
Naperville, Illinois · Withdrawn
GI Partners of Illinois - Southwest Gastroenterology
Oak Lawn, Illinois · Recruiting
Rockford Gastroenterology Associates, Ltd.
Rockford, Illinois · Recruiting
Springfield Clinic
Springfield, Illinois · Recruiting
Riverview Health
Westfield, Indiana · Recruiting
Hutchinson Clinic
Hutchinson, Kansas · Recruiting
Tri-State Gastroenterology Associates
Crestview Hills, Kentucky · Recruiting
Baton Rouge General Medical Center - Bluebonnet Campus
Baton Rouge, Louisiana · Recruiting
Combined Gastro LLC
Lafayette, Louisiana · Recruiting
GI Alliance
Metairie, Louisiana · Recruiting
Showing 40 of 101 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.